日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma

STELLAR:一项III期、随机、开放标签研究,比较依氟鸟氨酸联合洛莫司汀与单用洛莫司汀治疗复发性3级星形细胞瘤患者的疗效

Colman, Howard; Lombardi, Giuseppe; Wong, Eric T; Walbert, Tobias; Eoli, Marica; Lassman, Andrew B; Peereboom, David M; Kizilbash, Sani H; Kamiya-Matsuoka, Carlos; Pitz, Marshall W; Strowd, Roy E; Desjardins, Annick; Kumthekar, Priya; Mason, Warren; Pellerino, Alessia; Soffietti, Riccardo; Butowski, Nicholas; Forsyth, Peter A; Hamza, Mohamed A; Hau, Peter; Lallana, Enrico; Nabors, Burt; Piccioni, David; Uhlmann, Erik J; Welsh, Liam C; Wen, Patrick Y; Dietrich, Jorg; Wang, Chao; Levin, Victor A

Tumor antigen only (TAO) vaccine platforms for glioblastoma therapeutics: a systematic review of evidence from clinical trials

用于胶质母细胞瘤治疗的肿瘤抗原(TAO)疫苗平台:临床试验证据的系统评价

Chen, Hsien-Chung; Wong, Eric T; Sarangi, Sasmit; Elinzano, Heinrich; Kuburich, Nick A; Mani, Sendurai A; Ali, Rohaid; Cielo, Deus; Svokos, Konstantina A; Sampath, Prakash; Malik, Athar N; Lee, Christine K; Doberstein, Curtis E; Lawler, Sean E; Seyhan, Attila; El-Deiry, Wafik S; Chen, Clark C

miR-181d coordinates homologous recombination and anti-tumor immune responses in glioblastoma.

miR-181d 协调胶质母细胞瘤中的同源重组和抗肿瘤免疫反应。

Singh Gatikrushna, Singh Shilpi, Mohapatra Iteeshree, Hou Jay, Ni Andrew, Barik Debashis, Zheng Haoyi, Kim Stefan, Sharma Mayur, Lawler Sean, Vasudevan Shobha, Kokkoli Efrosini, Sarangi Sasmit, Elinzano Heinrich, Wong Eric T, Martinez-Moreno Margot, Gokaslan Ziya, El-Deiry Wafik, Chen Clark C

Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma

胶质母细胞瘤对贝伐珠单抗长期反应的分子相关性

Villano, John L; Garcia, Catherine R; Morgan, Rachael M; Zhang, Shulin; Kolesar, Jill; Mirza, Farhan A; Samec, Timothy; Xiu, Joanne; Rock, Stephanie; Kesari, Santosh; Lou, Emil; Aulakh, Sonikpreet; Glantz, Michael J; Wong, Eric T

Acquired resistance to molecularly targeted therapies for cancer

癌症分子靶向治疗的获得性耐药

Stubbs, Nolan M; Roady, Tyler J; Schwermann, Maximilian P; Eteshola, Elias O; MacDonald, William J; Purcell, Connor; Ryspayeva, Dinara; Verovkina, Nataliia; Tajiknia, Vida; Ghandali, Maryam; Voong, Viva; Lannigan, Alexis J; Raufi, Alexander G; Lawler, Sean; Holder, Sheldon L; Carneiro, Benedito A; Cheng, Liang; Safran, Howard P; Graff, Stephanie L; Dizon, Don S; Mani, Sendurai A; Seyhan, Attila A; Sobol, Robert W; Wong, Eric T; Chen, Clark C; Gokaslan, Ziya; Taylor, Martin S; Rivers, Brian M; El-Deiry, Wafik S

Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM

新诊断的胶质母细胞瘤中肿瘤内B细胞和干扰素特征与接受SurVaxM治疗的患者生存期延长相关。

Withers, Henry G; Figel, Sheila A; Qiu, Jingxin; Ahluwalia, Manmeet Singh; Reardon, David; Abad, Ajay P; Curry, William T; Wong, Eric T; Peereboom, David M; Dhawan, Andrew; Liu, Song; Ciesielski, Michael J; Fenstermaker, Robert A

Hydrogel and scalp/skin conductivities impact dose from tumor treating fields

水凝胶和头皮/皮肤电导率会影响肿瘤治疗场的剂量

Lok, Edwin; Liang, Olivia; Haack, Monika; Wong, Eric T

Effects of craniectomy defect on tumor-treating fields

颅骨切除术缺陷对肿瘤治疗场的影响

Lok, Edwin; Chang, Bryant; Vega, Rafael; Haack, Monika; Wong, Eric T

IGV-001 cellular immunotherapy for newly diagnosed glioblastoma: overcoming the logistic challenge

IGV-001细胞免疫疗法用于新诊断的胶质母细胞瘤:克服后勤挑战

Wong, Eric T; Cielo, Deus; Svokos, Konstantina; Doberstein, Curt; Sampath, Prakash; Donahue, John E; Punsoni, Michael; Rodrigues, Nuno; Rothell, Francesca; Edwards, Robert; Wang, Elaina; Riccelli, Tori; Chuck, Carlin; Shaaya, Elias A; Sastry, Rahul; Ali, Rohaid; Shao, Belinda; Abdulrazeq, Hael; Sun, Felicia W; Feler, Joshua; Santos Fontánez, Santos E; Nieves, Natalie Amaral; Dobertsein, Cody; Dailey, Jennifer; Yu, Christine; Sarangi, Sasmit; Elinzano, Heinrich; Boxerman, Jerrold L; Yu, Esther; Safran, Howard; Seyhan, Attila A; El-Deiry, Wafik S; Keith, Sharonda; Gokaslan, Ziya L; Chen, Clark C; Malik, Athar

Reduced EZH1/2 expression in imipridone-treated cells correlates with synergy following combinations with EZH1/2 or HDAC inhibitors in diffuse glioma and other tumors.

在用咪吡啶酮治疗的细胞中,EZH1/2 表达降低与弥漫性胶质瘤和其他肿瘤中 EZH1/2 或 HDAC 抑制剂联合用药后的协同作用相关

Zhang Yiqun, Huntington Kelsey E, Seyhan Attila A, Tapinos Nikos, Lulla Rishi R, Monje Michelle, Wong Eric T, Chen Clark C, El-Deiry Wafik S